Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KURA NASDAQ:ORIC NASDAQ:REPL NASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$9.05+2.1%$9.31$5.45▼$12.49$786.54M0.362.20 million shs1.30 million shsORICOric Pharmaceuticals$8.27+5.8%$9.03$7.23▼$14.93$809.51M1.041.65 million shs1.56 million shsREPLReplimune Group$8.88+3.0%$5.25$1.50▼$13.24$711.78M0.916.86 million shs1.97 million shsRNAAvidity Biosciences$12.37-0.5%$13.09$11.40▼$16.77$211.60M0.93518,507 shs103,634 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology+2.07%+1.03%-8.47%+2.43%+28.03%ORICOric Pharmaceuticals+3.71%-2.49%-11.44%-34.29%-16.72%REPLReplimune Group+1.77%-12.66%+110.76%+20.73%-11.86%RNAAvidity Biosciences+6.51%+1.06%-5.40%-9.60%-61.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$9.05+2.1%$9.31$5.45▼$12.49$786.54M0.362.20 million shs1.30 million shsORICOric Pharmaceuticals$8.27+5.8%$9.03$7.23▼$14.93$809.51M1.041.65 million shs1.56 million shsREPLReplimune Group$8.88+3.0%$5.25$1.50▼$13.24$711.78M0.916.86 million shs1.97 million shsRNAAvidity Biosciences$12.37-0.5%$13.09$11.40▼$16.77$211.60M0.93518,507 shs103,634 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology+2.07%+1.03%-8.47%+2.43%+28.03%ORICOric Pharmaceuticals+3.71%-2.49%-11.44%-34.29%-16.72%REPLReplimune Group+1.77%-12.66%+110.76%+20.73%-11.86%RNAAvidity Biosciences+6.51%+1.06%-5.40%-9.60%-61.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKURAKura Oncology 2.69Moderate Buy$25.58182.69% UpsideORICOric Pharmaceuticals 2.76Moderate Buy$18.92128.74% UpsideREPLReplimune Group 1.70Reduce$4.88-45.10% DownsideRNAAvidity Biosciences 2.33Hold$70.29468.26% UpsideCurrent Analyst Ratings BreakdownLatest RNA, REPL, ORIC, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026ORICOric Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/8/2026ORICOric Pharmaceuticals BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/4/2026KURAKura Oncology Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026KURAKura Oncology CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/4/2026KURAKura Oncology Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/3/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$2.00 ➝ $6.005/29/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$8.005/28/2026KURAKura Oncology OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/28/2026KURAKura Oncology Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKURAKura Oncology$67.48M11.91N/AN/A$2.00 per share4.53ORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ARNAAvidity Biosciences$36.68M5.77N/AN/A$10.88 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKURAKura Oncology-$278.67M-$3.35N/AN/AN/A-411.19%-141.95%-43.28%8/6/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)REPLReplimune Group-$247.30M-$3.44N/AN/AN/AN/A-102.69%-72.22%6/12/2026 (Estimated)RNAAvidity Biosciences-$322.30MN/AN/AN/AN/A-3,650.39%-44.92%-39.57%N/ALatest RNA, REPL, ORIC, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2026Q4 2026REPLReplimune Group-$0.73N/AN/AN/A$5.57 millionN/A5/14/2026Q1 2026RNAAvidity Biosciences-$1.05-$0.97+$0.08-$0.97$2.00 million$19.64 million5/12/2026Q1 2026KURAKura Oncology-$0.88-$0.83+$0.05-$0.83$25.97 million$18.27 million5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKURAKura OncologyN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKURAKura Oncology0.096.156.14ORICOric PharmaceuticalsN/A16.3316.33REPLReplimune Group0.335.605.60RNAAvidity BiosciencesN/A9.2011.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKURAKura OncologyN/AORICOric Pharmaceuticals95.05%REPLReplimune Group92.53%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipKURAKura Oncology7.60%ORICOric Pharmaceuticals5.70%REPLReplimune Group5.20%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKURAKura Oncology13088.77 million82.03 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionableREPLReplimune Group21082.57 million78.28 millionOptionableRNAAvidity Biosciences19017.11 million149.21 millionOptionableRNA, REPL, ORIC, and KURA HeadlinesRecent News About These CompaniesNovartis RNA drug acquired in $12B Avidity deal notches a trial winJune 12 at 1:16 AM | biopharmadive.comBAtrium Therapeutics Reports First Quarter 2026 Financial ResultsMay 14, 2026 | prnewswire.comAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationApril 23, 2026 | prnewswire.comAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 20, 2026 | prnewswire.comNovartis Uses US Bond Issue To Expand RNA And Peptide PipelineMarch 19, 2026 | uk.finance.yahoo.comNovartis acquisition spin-off pioneers RNA therapeutics for the heartMarch 19, 2026 | finance.yahoo.comAtrium TherapeuticsMarch 5, 2026 | thepharmaletter.comTAvidity Biosciences Completes Merger and Plans Nasdaq DelistingMarch 4, 2026 | theglobeandmail.comWhich Is a Better Investment, Exact Sciences Corporation or Avidity Biosciences, Inc. Stock?March 2, 2026 | aaii.comAAtrium spins out of Avidity, aiming to target rare heart diseases with RNAFebruary 27, 2026 | biopharmadive.comBAtrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic CardiomyopathiesFebruary 27, 2026 | prnewswire.comAvidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceFebruary 26, 2026 | prnewswire.comAvidity Biosciences, Inc.: Avidity Biosciences Announces Expected Record Date for Spin-OffFebruary 26, 2026 | finanznachrichten.deAvidity Biosciences, Inc.: Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of StockholdersFebruary 24, 2026 | finanznachrichten.deAvidity Biosciences Advances Toward Novartis Merger CompletionFebruary 23, 2026 | tipranks.comAvidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of StockholdersFebruary 23, 2026 | prnewswire.comThe New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1February 18, 2026 | prnewswire.comAvidity Biosciences Announces Expected Record Date for Spin-OffFebruary 2, 2026 | prnewswire.comCiti Remains a Hold on Avidity Biosciences (RNA)January 31, 2026 | theglobeandmail.comSonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product DevelopmentJanuary 28, 2026 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfBy Thomas Hughes | May 22, 2026The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector GainsBy Jeffrey Neal Johnson | May 14, 2026Japan's Stealth Bull Market: How U.S. Investors Can Get ExposureBy Chris Markoch | May 17, 2026Amazon vs. Alibaba: One Is Clearly The Better Value Play right NowBy Sam Quirke | May 14, 2026RNA, REPL, ORIC, and KURA Company DescriptionsKura Oncology NASDAQ:KURA$9.05 +0.19 (+2.14%) Closing price 04:00 PM EasternExtended Trading$9.06 +0.00 (+0.06%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Oric Pharmaceuticals NASDAQ:ORIC$8.27 +0.45 (+5.75%) Closing price 04:00 PM EasternExtended Trading$7.72 -0.55 (-6.59%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Replimune Group NASDAQ:REPL$8.88 +0.26 (+3.02%) Closing price 04:00 PM EasternExtended Trading$8.85 -0.04 (-0.39%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Avidity Biosciences NASDAQ:RNA$12.37 -0.06 (-0.48%) As of 04:00 PM EasternAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
